William Blair Reiterates an 'Outperform' on Dynavax (DVAX); Heplisav VRBPAC Panel Set - What to Watch For
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Maintains a 'Buy' on Dynavax Technologies (DVAX); Next Catalyst For Heplisav
August 29, 2012 7:33 AM EDTJefferies maintains a 'Buy' on Dynavax Technologies (NASDAQ: DVAX) price target of $6.00.
Analyst, Thomas Wei, said, "DVAX announced that an FDA advisory committee meeting for Heplisav will be held on November 14-15, in advance of its February 24 action date. We continue to believe... More
Dynavax (DVAX) Announces November 14-15 FDA AdCom for HEPLISAV
August 28, 2012 9:07 AM EDTDynavax Technologies Corporation (NASDAQ: DVAX) said the FDA informed the Company that its Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to discuss HEPLISAV at its meeting on November 14-15, 2012.
Dynavax's Biologic License Application (BLA) for HEPLISAV, pursuing an indication for... More
